Metabolic syndrome and 10-year cardiovascular risk among HIV-positive and HIV-negative adults: A cross-sectional study. Issue 27 (2nd July 2020)

• Record Type: Journal Article
• Authors: Masyuko, Sarah J.; Page, Stephanie T.; Kinuthia, John; Osoti, Alfred O.; Polyak, Stephen J.; Otieno, Fredrick C.; Kibachio, Joseph M.; Mogaka, Jerusha N.; Temu, Tecla M.; Zifodya, Jerry S.; Otedo, Amos; Nakanjako, Damalie; Hughes, James P.; Farquhar, Carey
• Other Names: Schaller. Bernhard section editor.
• Is Part Of: Medicine. Volume 99:Issue 27(2020)
• Publication Date: 2020-07-02
• Subjects: cardiovascular risk score -- HIV -- Kenya -- metabolic syndrome; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000020845
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: To determine the prevalence and correlates of metabolic syndrome (MetS) and compare 10-year cardiovascular disease (CVD) risk among Kenyan adults with and without HIV infection. We conducted a cross-sectional study among adults ≥30 years of age with and without HIV infection seeking care at Kisumu County Hospital. Participants completed a health questionnaire and vital signs, anthropomorphic measurements, and fasting blood were obtained. MetS was defined using 2009 Consensus Criteria and 10-year Atherosclerotic CVD (ASCVD) risk score was calculated. Chi-square, independent t tests, Wilcoxon ranksum test and multivariable logistic regression were used to determine differences and associations between HIV and MetS, CVD risk factors and ASCVD risk score. A total of 300 people living with HIV (PLWHIV) and 298 HIV-negative participants with median age 44 years enrolled, 50% of whom were female. The prevalence of MetS was 8.9% overall, but lower among PLWHIV than HIV-negative participants (6.3% vs 11.6%, respectively; P = .001). The most prevalent MetS components were elevated blood pressure, decreased high density lipoprotein, and abdominal obesity. Adjusting for covariates, PLWHIV were 66% less likely to have MetS compared to HIV-negative participants (adjusted odds ratio [aOR] 0.34; 95% confidence interval [95%CI] 0.18, 0.65; P = .005). Median ASCVD risk score was also lower among PLWHIV compared to HIV-negative participants (1.7% vs 3.0%, P = .002). MetS was more common among HIV-negative than HIV-positive adults, and HIV-negative adults were at greater risk for CVD compared to PLWHIV. These data support integration of routine CVD screening and management into health programs in resource-limited settings, regardless of HIV status. Abstract : Supplemental Digital Content is available in the text